Stanford researchers have developed an LVCTM3 system for producing lentiviral vectors and other viral particles, offering a cost-effective, simplified and scalable solution for various applications from gene therapy to vaccine development.
Researchers at Stanford University have developed a novel platform for genetically engineering cells within a living organism, circumventing previous limitations related to accessing target tissues and the size of the genetic payload.
Researchers at Stanford have developed a CRISPR-based system to degrade viral RNA, with potential applications as both an anti-viral therapeutic and a prophylactic treatment against influenza, SARS-CoV-2, and other viruses.
Researchers in the Mark Kay group have identified a method to increase the rates of AAV vector-mediated HR (AAV-HR) in mammalian cells, increasing the efficiency of gene targeting rate
Researchers at Stanford have developed methods to overcome the limited packaging capacity of adeno-associated virus (AAV) vectors and enable their use in integration of large transgenes.
Researchers in Prof. Mark Kay's laboratory have developed recombinant adeno-associated viral (AAV) capsid proteins that transduce human primary hepatocytes at high efficiency in vitro and in vivo.